COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

2.53%

Decreased from previous period

Growth of 2.53% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

2.00%

Decreased from previous period

Cost growth of 2.00% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

4.70%

Increased from previous period

Growth of 4.70% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

2.12%

Increased from previous period

Margin change of 2.12% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

-100.00%

G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.

Selling & Marketing Expenses Growth

-100.00%

Marketing expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.

Other Expenses Growth

-11.20%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

0.98%

Decreased from previous period

Operating expenses growth exceeding 1.5x Healthcare median of 0.48%. Jim Chanos would check for waste.

Total Costs & Expenses Growth

1.84%

Decreased from previous period

Total costs change of 1.84% versus flat Healthcare costs. Walter Schloss would verify control.

Interest Expense Growth

-7.14%

Decreased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

-4.46%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

20.59%

Increased from previous period

EBITDA change of 20.59% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

17.61%

Increased from previous period

Margin change of 17.61% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

19.88%

Increased from previous period

Operating income growth while Healthcare declines. Peter Lynch would examine advantages.

Operating Margin Growth

16.92%

Increased from previous period

Margin change of 16.92% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

367.07%

Increased from previous period

Other expenses growth exceeding 1.5x Healthcare median of 2.07%. Jim Chanos would check for issues.

Pre-Tax Income Growth

33.70%

Increased from previous period

Income change of 33.70% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

30.39%

Increased from previous period

Margin change of 30.39% versus flat Healthcare. Walter Schloss would verify quality.

Income Tax Expense Growth

125.78%

Increased from previous period

Tax expense change of 125.78% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

11.98%

Increased from previous period

Income change of 11.98% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

9.21%

Increased from previous period

Margin change of 9.21% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

11.99%

Increased from previous period

EPS change of 11.99% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

11.99%

Increased from previous period

Diluted EPS change of 11.99% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

-0.00%

Share count reduction while Healthcare median is 0.33%. Seth Klarman would investigate strategy.

Share Count Growth (Diluted)

-0.00%

Diluted share reduction while Healthcare median is 0.34%. Seth Klarman would investigate strategy.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

2.53%

Decreased from previous period

Growth of 2.53% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

2.00%

Decreased from previous period

Cost growth of 2.00% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

4.70%

Increased from previous period

Growth of 4.70% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

2.12%

Increased from previous period

Margin change of 2.12% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

-100.00%

G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.

Selling & Marketing Expenses Growth

-100.00%

Marketing expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.

Other Expenses Growth

-11.20%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

0.98%

Decreased from previous period

Operating expenses growth exceeding 1.5x Healthcare median of 0.48%. Jim Chanos would check for waste.

Total Costs & Expenses Growth

1.84%

Decreased from previous period

Total costs change of 1.84% versus flat Healthcare costs. Walter Schloss would verify control.

Interest Expense Growth

-7.14%

Decreased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

-4.46%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

20.59%

Increased from previous period

EBITDA change of 20.59% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

17.61%

Increased from previous period

Margin change of 17.61% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

19.88%

Increased from previous period

Operating income growth while Healthcare declines. Peter Lynch would examine advantages.

Operating Margin Growth

16.92%

Increased from previous period

Margin change of 16.92% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

367.07%

Increased from previous period

Other expenses growth exceeding 1.5x Healthcare median of 2.07%. Jim Chanos would check for issues.

Pre-Tax Income Growth

33.70%

Increased from previous period

Income change of 33.70% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

30.39%

Increased from previous period

Margin change of 30.39% versus flat Healthcare. Walter Schloss would verify quality.

Income Tax Expense Growth

125.78%

Increased from previous period

Tax expense change of 125.78% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

11.98%

Increased from previous period

Income change of 11.98% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

9.21%

Increased from previous period

Margin change of 9.21% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

11.99%

Increased from previous period

EPS change of 11.99% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

11.99%

Increased from previous period

Diluted EPS change of 11.99% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

-0.00%

Share count reduction while Healthcare median is 0.33%. Seth Klarman would investigate strategy.

Share Count Growth (Diluted)

-0.00%

Diluted share reduction while Healthcare median is 0.34%. Seth Klarman would investigate strategy.

Select Chart Metric: